HOME >> BIOLOGY >> NEWS
Novel antiviral drug concept targets number of human viruses

protein would kill the cell," says Priscilla A. Schaffer, Ph.D., chair of microbiology and senior author on the study. "We've discovered that's not true -- by inhibiting a specific type of cellular enzyme, we've been able to completely block all viral activity without damaging the cells."

The pivotal enzymes are called cyclin-dependent kinases, or cdks. Cells use cdks, along with other proteins, to drive and coordinate cell division. Many viruses, too, rely on cellular cdks for their replication.

The Penn scientists were aware that Laurent Meijer, Ph.D., and his colleagues at the Centre National de la Recherche Scientifique in Roscoff, France, had developed and characterized a variety of cdk-specific inhibitors. With Meijer's assistance, they introduced his inhibitors into HSV-infected cells to test their antiviral theory. What they found was that viral replication ceased while the cells continued to be healthy.

Since the cells depend on cdks for their division but not for many other essential functions, they simply stop dividing in the presence of the drugs. But HSV depends absolutely on cdks for at least three steps in its life cycle, as is likely the case for other viruses, making it vulnerable to cdk inhibitors in multiple ways.

Additionally, the focused reliance of the viruses on cdks, combined with the fact that cdks are cellular, not viral, proteins, strongly suggests that the viruses will have a vanishingly small chance of mutating to develop resistance to cdk inhibitors.

Among the strains of virus completely inactivated by the cdk inhibitors in the Penn experiments were HSV-1 and HSV-2, which chronically infect 80 percent and 20 percent of the world's population respectively and are responsible for painful oral, and genital lesions, themselves a risk factor for sexually transmitted diseases and other health problems. HSV infections can also result in blindness and occasionally in fatal encephalitis.

Thomas Albrecht, Ph.
'"/>

Contact: Franklin Hoke
frank.hoke@nasw.org
215-662-2560
University of Pennsylvania School of Medicine
20-Apr-2000


Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
Breaking Biology News(10 mins):
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics ... The move comes after the company changed focus to making analytical tools for ... and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart ...
(Date:4/19/2017)... , ... April 19, 2017 , ... ... which makes educational webinars accessible to novices as well as experienced users, ... variables of commonly performed coagulation screening tests. , Hemostasis testing quality is ...
(Date:4/19/2017)... 19, 2017 Veracyte, Inc. ... it will report its first quarter 2017 financial ... 2017. Following the announcement, Veracyte,s management will host a live ... discuss the company,s financial results and business progress. ... may be accessed by visiting Veracyte,s website at  http://investor.veracyte.com . ...
(Date:4/18/2017)... Texas (PRWEB) , ... April 18, 2017 , ... For ... Research Associates, co-members in the VaxCorps vaccine consortium, were named one of the top ... finalist since the inception of this category; winning the award four times previously, and ...
Breaking Biology Technology:
Cached News: